“Avamed Synergy opens investment round to raise €5M pre-market”

The biotech innovation company aims to finish paying for the pilot tests of its Fluxus development and to acquire financial strength to negotiate with partners interested in the technological project

Avamed Synergy, based in Distrito Digital (Alicante), opens a new financing round of five million euros. The objective is to finish paying for the pilot tests of its Fluxus development and to acquire “financial strength” when negotiating with partners interested in the technological development. The company is currently looking for partners to commercialize Fluxus and, in fact, expects to reach an agreement before the end of the year.

It is currently its third investment round to raise private capital, after recently closing a round of internal expansion with the investment partners that backed Fluxus in its beginnings.

In this way, Avamed Synergy continues to grow steadily and to expand its team of engineers and researchers, with a clear commitment to innovation and to its R&D&I department, a key factor in the development of Fluxus. Fluxus has aroused great interest among the medical community by incorporating a technology that revolutionizes analysis and decision making in predictive oncology. Fluxus Artificial Intelligence greatly empowers oncologists and surgeons in their image analysis and decision making.

The platform, which will be integrated into hospital work environments, thus introduces a significant differentiation from current systems. Based on its unique intelligent and predictive modelling, it is set to be the most precise and demanding technological offering on the market. In this case, it is not just a matter of seeing the tumour, but of understanding its future behaviour with the host.

This innovation is aligned with and supported by significant market growth forecasts, as the global market for oncology and surgical treatment is expected to grow to 7.77 billion euros. With fluxus expected to reach 91.8 million euros in annual revenues, targeting a 5% market share in Spain alone. The company's team also expects to reach the market in the second half of 2026, once it is certified as a “Medical Device” and CE marked.

Avamed Synergy is backed with a multidisciplinary team of experts, including industry leaders such as neurosurgeons, biomedical researchers and Artificial Intelligence specialists. The international roadmap anticipates scaling beyond Spain to Europe, LATAM, North America and Asia. In addition, it will expand into more markets by 2028.

Lucas Díez, CEO and founder of Avamed Synergy, stresses the importance of the tool in the healthcare field: "The mission with Fluxus goes beyond diagnosis. We are innovating with predictive simulations that offer 95% fewer false negatives and a 70% improvement in treatment efficacy". He is also optimistic about the success of this investment round: "Investors in Avamed Synergy will not just fund an innovative product; they will be partners in a movement to redefine the way cancer is treated.